Shares fall as US Food and Drug panel rejects new Australian biotech drug

By Bianca Hartge-Hazelman
Updated April 24 2014 - 6:08am, first published 5:41am

Shares in Australian pharmaceutical firm QRxPharma have plummeted 80 per cent in a major shareholder revolt after the company failed to win regulatory approval for its painkiller drug MoxDuo to be released in the US.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Launceston news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.